Cardiovascular Safety of Long Acting Beta Agonist-Inhaled Corticosteroid Combination Products in Adult Patients with Asthma: A Systematic Review

被引：9
作者：
Iftikhar, Imran H. [1 ]
Imtiaz, Muhammad [1 ]
Brett, Allan S. [2 ]
Amrol, David J. [3 ]
机构：
[1] Univ S Carolina, Dept Med, Div Pulm Crit Care & Sleep Med, Columbia, SC 29203 USA
[2] Univ S Carolina, Dept Med, Div Gen Internal Med, Columbia, SC 29203 USA
[3] Univ S Carolina, Dept Med, Div Allergy Asthma & Immunol, Columbia, SC 29203 USA
来源：
LUNG | 2014年 / 192卷 / 01期
关键词：
Fluticasone propionate; Fluticasone furoate; Mometasone furoate; Salmeterol; Formoterol; Asthma; CARDIAC-ARRHYTHMIAS; SALMETEROL; EXACERBATIONS; METAANALYSIS; BUDESONIDE/FORMOTEROL; MANAGEMENT; MORTALITY; RISK; COPD;
D O I：
10.1007/s00408-013-9525-x
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Long-acting beta agonists and inhaled corticosteroids combination products (LABA-ICS) are widely used in the treatment of asthma. However, there appears to be little data on their cardiovascular safety. The purpose of this study was to conduct a systematic review of the available studies and trials on the cardiovascular safety of LABA-ICS in adults with asthma. Two independent reviewers screened citations from PubMed and National Clinical Trials registry to identify studies and trials on the cardiovascular effects of LABA-ICS in patients with asthma. A total of 15 studies (with 17 cohorts on LABA-ICS to compare with a comparator or placebo) with 5,440 total study participants met the inclusion criteria. Two studies on budesonide-formoterol and one on fluticasone-salmeterol reported treatment emergent cardiovascular adverse events, all of which were dysrhythmias. For comparison, the pooled estimate of the Peto odds ratio (0.72; 95 % confidence interval [CI] 0.17-3; p = 0.65) and the summary risk ratio (0.77; 95 % CI 0.26-2.3; p = 0.64) indicated a nonsignificant difference between LABA-ICS and comparator/placebo groups. Our systematic review found that few studies and trials reported treatment emergent cardiovascular adverse events with LABA-ICS. However, the Peto odds ratio and risk ratio for these outcomes was statistically nonsignificant. This suggests that LABA-ICS products may have a safe cardiovascular profile in asthma patients.
引用
收藏
页码：47 / 54
页数：8
相关论文
共 35 条
  • [1] AstraZeneca, STUD INV SAF EFF HIG
  • [2] AstraZeneca, COMP SYMB AS NEED BR
  • [3] AstraZeneca, COMP SYMBICORT PMDI
  • [4] AstraZeneca, EFF STUD COMP SYMBIC
  • [5] AstraZeneca, PHASE4 SYMB VERS PUL
  • [6] Risk of mortality and heart failure exacerbations associated with inhaled β-adrenoceptor agonists among patients with known left ventricular systolic dysfunction
    Au, DH
    Udris, EM
    Fan, VS
    Curtis, JR
    McDonell, MB
    Fihn, SD
    [J]. CHEST, 2003, 123 (06) : 1964 - 1969
  • [7] Global strategy for asthma management and prevention: GINA executive summary
    Bateman, E. D.
    Hurd, S. S.
    Barnes, P. J.
    Bousquet, J.
    Drazen, J. M.
    FitzGerald, M.
    Gibson, P.
    Ohta, K.
    O'Byrne, P.
    Pedersen, S. E.
    Pizzichini, E.
    Sullivan, S. D.
    Wenzel, S. E.
    Zar, H. J.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2008, 31 (01) : 143 - 178
  • [8] SEREVENT NATIONWIDE SURVEILLANCE STUDY - COMPARISON OF SALMETEROL WITH SALBUTAMOL IN ASTHMATIC-PATIENTS WHO REQUIRE REGULAR BRONCHODILATOR TREATMENT
    CASTLE, W
    FULLER, R
    HALL, J
    PALMER, J
    [J]. BRITISH MEDICAL JOURNAL, 1993, 306 (6884) : 1034 - 1037
  • [9] Regular treatment with formoterol for chronic asthma: serious adverse events
    Cates, Christopher J.
    Cates, Matthew J.
    Lasserson, Toby J.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2008, (04):
  • [10] Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia
    Cazzola, M
    Imperatore, F
    Salzillo, A
    Di Perna, F
    Calderaro, F
    Imperatore, A
    Matera, MG
    [J]. CHEST, 1998, 114 (02) : 411 - 415
1234